Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

752.59 +3.08 (+0.41%)
Streaming Delayed Price Updated: 3:31 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
Via Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Value Stocks Worth Buying at These 52-Week Highs
While these value stocks to buy are trading near their 52-week highs, they still have plenty of gas left in the tank for investors. 
Via InvestorPlace
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Regeneron and Sarepta Therapeutics have been on fire so far this year. 
Via The Motley Fool
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.